Clinical efficacy and safety: Clinical pharmacology and pharmacokinetics

  • Email
  • Help

This page lists the European Medicines Agency's scientific guidelines on clinical pharmacology and pharmacokinetics, which concern the study of medicines and their action in the human body.

There is a separate a list on product-specific bioequivalence guidance.

If you have comments on a document that is open for consultation, use the form for submission of comments on scientific guidelines.

Please note that the Efficacy Working Party secretariat e-mail address (ewpsecretariat@ema.europa.eu) no longer exists. Therefore, please submit your comments from now on to the following e-mail address: pkwpsecretariat@ema.europa.eu.

TopicDocumentsReference numberPublication dateEffective dateRemarks
Qualification and reporting of physiologically-based pharmacokinetic (PBPK) modelling and analysesConcept paper EMA/CHMP/211243/2014Released for consultation June 2014 Deadline for comments 30 September 2014
Development of a guideline on the demonstration of therapeutic equivalence for locally applied and locally acting products in the gastrointestinal tractConcept paperEMA/CHMP/558326/2013Released for consultation October 2013 Deadline for comments 31 December 2013
Pharmacokinetic and clinical evaluation of modified-release dosage forms

Adopted guideline

Draft guideline

 

EMA/CHMP/EWP/280/96 Rev. 1

November 2014

 

June 2015

 

 
Modified-release oral and transdermal dosage forms: Section IIAdopted guidelineEMA/CPMP/EWP/280/96/Corr.1 (28/05/09)July 1999January 2000 
Data requirements for intravenous liposomal products developed with reference to an innovator liposomal product

Overview of comments

Adopted reflection paper

Draft reflection paper

EMA/CHMP/806058/2009/Rev. 2

 

March 2013  
Use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products

Adopted guideline

Draft guideline

Concept paper

EMA/CHMP/37646/2009February 2012August 2012 
Investigation of drug interactions

Overview of comments

Adopted guideline

Draft guideline

Concept paper

CPMP/EWP/560/95/Rev. 1July 2012January 2013 
Investigation of drug interactionsAdopted guidelineCPMP/EWP/560/95 December 1997June 1998 
Investigation of bioequivalence

Overview of comments

Adopted guideline

Draft guideline

Concept paper

Concept paper

CPMP/EWP/QWP/1401/98 Rev. 1January 2010August 2010 
Appendix IV of the guideline on the investigation on bioequivalence (CPMP/EWP/QWP/1401/98 Rev.1): Presentation of biopharmaceutical and bioanalytical data in module 2.7.1

Overview of comments

Adopted guideline

Draft guideline

 

EMA/CHMP/600958/2010November 2011June 2012 
Positions on specific questions addressed to the
Pharmacokinetics Working Party

Questions and answers

EMA/618604/08 Rev. 9May 2014  
Bioanalytical method validation

Overview of comments

Adopted guideline

Draft guideline

Concept paper

EMEA/CHMP/EWP/192217/09August 2011February 2012 
Clinical investigation of the pharmacokinetics of therapeutic proteins

Overview of comments

Adopted guideline

Draft guideline

CPMP/EWP/89249/04February 2007July 2007 
Role of pharmacokinetics in the development of medicinal products in the paediatric population

Overview of comments

Adopted guideline

CHMP/EWP/147013/04July 2006January 2007 
Need to develop an appendix to the guideline on bioequivalence regarding the presentation of biopharmaceutical and bioanalytical data in application dossiersConcept paperEMA/CHMP/EWP/82259/2010Released for consultation April 2010 Deadline for comments 31 July 2010
Strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products

Overview of comments

Adopted guideline

Draft guideline

CHMP/SWP/28367/07July 2007September 2007 
Reporting the results of population pharmacokinetic analyses

Overview of comments

Adopted guideline

Draft guideline

CHMP/EWP/185990/06July 2007January 2008 
Addendum to the note for guidance on the investigation of bioavailability and bioequivalence: Evaluation of bioequivalence of highly variable drugs and drug products CHMP/EWP/147231/06  Deleted.
This topic will be addressed in the revision of the note for guidance on the investigation of bioavailability and bioequivalence (CHMP/EWP/200943/07)
Evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic functionAdopted guidelineCPMP/EWP/2339/02February 2005August 2005 
Evaluation of the pharmacokinetics of medicinal products in patients with decreased renal functionDraft guidelineEMA/83874/2014 Rev 1Released for consultation March 2014 Deadline for comments 31 August 2014
Need for revision of the note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal functionConcept paperEMA/CHMP/203926/2012Released for consultation June 2012 Deadline for comments 31 July 2012
Evaluation of the pharmacokinetics of medicinal products in patients with impaired renal functionAdopted guidelineCHMP/EWP/225/02July 2004 December 2004 
Points to consider on the clinical requirements of modified-release products released as a line extension of an existing marketing authorisationAdopted guidelineCPMP/EWP/1875/03December 2003June 2003 
Pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal productsAdopted guidelineCPMP/EWP/2655/99July 2000February 2001 
Need for revision of the note for guidance on modified-release oral and transdermal dosage forms: section II (pharmacokinetic and clinical evaluation)Concept paperEMA/CHMP/1303/2010Released for consultation May 2010 Deadline for comments 31 August 2010
Pharmacokinetic studies in manAdopted guideline3CC3AOctober 1998  

How useful is this page?

Average rating:

 Based on 45 ratings

Add your rating:

See all ratings
6 ratings
1 ratings
1 ratings
9 ratings
28 ratings